195 related articles for article (PubMed ID: 29033181)
1. Pathobiology of HER 2 positive small invasive (T1a,b) breast cancer: "A wolf in sheep's clothing".
Bezić J; Šamija Projić I; Projić P; Meljanac Salopek K; Živković PM; Božić J; Tomić S
Pathol Res Pract; 2017 Dec; 213(12):1510-1514. PubMed ID: 29033181
[TBL] [Abstract][Full Text] [Related]
2. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.
Ugras S; Stempel M; Patil S; Morrow M
Ann Surg Oncol; 2014 Nov; 21(12):3780-6. PubMed ID: 24952028
[TBL] [Abstract][Full Text] [Related]
4. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients.
Rivadeneira DE; Simmons RM; Christos PJ; Hanna K; Daly JM; Osborne MP
J Am Coll Surg; 2000 Jul; 191(1):1-6; discussion 6-8. PubMed ID: 10898177
[TBL] [Abstract][Full Text] [Related]
6. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
Tan P; Cady B; Wanner M; Worland P; Cukor B; Magi-Galluzzi C; Lavin P; Draetta G; Pagano M; Loda M
Cancer Res; 1997 Apr; 57(7):1259-63. PubMed ID: 9102210
[TBL] [Abstract][Full Text] [Related]
7. Presenting features of breast cancer differ by molecular subtype.
Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?
Lin H; Zheng H; Ge C; Wang Q; Tang W; Zhang X; Zhou S; Jin X; Xu X; Du J; Fu J
Clin Breast Cancer; 2020 Dec; 20(6):503-510. PubMed ID: 32653474
[TBL] [Abstract][Full Text] [Related]
9. Near-diploid hyperploidy in early breast cancer (T1a,b) is associated with higher risk of lymph node involvement.
Bezić J; Samija-Projić I; Projić P; Ljubković J; Tomaš-Zekić S; Marinović-Guić M; Tomić S
Pathol Oncol Res; 2013 Jan; 19(1):71-7. PubMed ID: 22927063
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients.
Majid S; Rydén L; Manjer J
World J Surg Oncol; 2018 Mar; 16(1):54. PubMed ID: 29530065
[TBL] [Abstract][Full Text] [Related]
12. Favorable results of patients with pT1a, b, c, lymph node-negative early breast cancer in the long interval.
Bulut N; Ulas A; Altundag K
J Cancer Res Ther; 2019; 15(5):1051-1056. PubMed ID: 31603109
[TBL] [Abstract][Full Text] [Related]
13. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
[TBL] [Abstract][Full Text] [Related]
14. Pathology and behavior of small breast carcinomas.
Meyer JS; Fahrner M; Daniel FC
Semin Diagn Pathol; 1999 Aug; 16(3):257-68. PubMed ID: 10490202
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
16. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
[TBL] [Abstract][Full Text] [Related]
17. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
[TBL] [Abstract][Full Text] [Related]
18. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
Lengyel E; Prechtel D; Resau JH; Gauger K; Welk A; Lindemann K; Salanti G; Richter T; Knudsen B; Vande Woude GF; Harbeck N
Int J Cancer; 2005 Feb; 113(4):678-82. PubMed ID: 15455388
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
20. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Hanrahan EO; Valero V; Gonzalez-Angulo AM; Hortobagyi GN
J Clin Oncol; 2006 May; 24(13):2113-22. PubMed ID: 16648513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
